Pular para o conteúdo principal

ETHNOS_APP

Início • Busca • Periódicos • Lista 0

Stefan Mauss

Dados Biográficos

ID7450074
NOMEStefan Mauss
PRENOMESStefan
SOBRENOMEMauss
ASSINATURAMAUSS S
AFILIAÇÕESCenter for HIV and Hepatogastroenterology
ORCID0009-0007-2657-3738
VERIFICADOSim
TOTAL DE OBRAS7
TOTAL DE CITAÇÕES0
TOTAL COMO AUTOR7
TOTAL COMO EDITOR0
PRIMEIRO ANO DE PUBLICAÇÃO2015
ANO MAIS RECENTE DE PUBLICAÇÃO2023
ÍNDICE H0
  • Additional challenges in reaching hepatitis C elimination goals in Germany due to the Covid-19 pandemic - descriptive analysis of drug prescription data from January 2018 to June 2021

    Open Access•Emily Meyer, Emily D Meyer et al.•ARTICLE•Frontiers in Public Health•2023

    Effectively treating hepatitis C viral (HCV) infections prevents sequelae and onward transmission. In Germany, HCV drug prescriptions have declined since 2015. During the COVID-19 pandemic, lockdowns impacted the access to HCV care services and HCV treatment. We assessed if the COVID-19 pandemic further decreased treatment prescriptions in Germany. We built log-linear models with monthly HCV drug prescription data from pharmacies from January 201…

  • Recommandations pour la prise en charge de l’infection par le virus de l’hépatite C chez les usagers de drogues par injection

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2023

  • Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2023

  • Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2023

  • Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019

    Open Access•Anna Maisa, Christian Kollan et al.•ARTICLE•Frontiers in Public Health•2021

    Background: Germany is a low prevalence country for hepatitis B virus (HBV) infection with higher prevalence in vulnerable groups. The number of treated chronic hepatitis B (CHB) patients is unknown. We aimed to determine the number of CHB patients treated with nucleos(t)ide analogs (NUCs), the treatment costs within the statutory health insurance (SHI) in Germany and per patient per month. Methods: Data on pharmacy bills of NUCs to patients with…

  • Global prevalence and genotype distribution of hepatitis C virus infection in 2015

    Open Access•Sarah Blach, Stefan Zeuzem et al.•ARTICLE•The Lancet Gastroenterology &…•2017

  • Recommendations for the management of hepatitis C virus infection among people who inject drugs

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2015

Sem obras proeminentes nesta página.

  • Recommendations for the management of hepatitis C virus infection among people who inject drugs

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2015

  • Global prevalence and genotype distribution of hepatitis C virus infection in 2015

    Open Access•Sarah Blach, Stefan Zeuzem et al.•ARTICLE•The Lancet Gastroenterology &…•2017

  • Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019

    Open Access•Anna Maisa, Christian Kollan et al.•ARTICLE•Frontiers in Public Health•2021

    Background: Germany is a low prevalence country for hepatitis B virus (HBV) infection with higher prevalence in vulnerable groups. The number of treated chronic hepatitis B (CHB) patients is unknown. We aimed to determine the number of CHB patients treated with nucleos(t)ide analogs (NUCs), the treatment costs within the statutory health insurance (SHI) in Germany and per patient per month. Methods: Data on pharmacy bills of NUCs to patients with…

  • Additional challenges in reaching hepatitis C elimination goals in Germany due to the Covid-19 pandemic - descriptive analysis of drug prescription data from January 2018 to June 2021

    Open Access•Emily Meyer, Emily D Meyer et al.•ARTICLE•Frontiers in Public Health•2023

    Effectively treating hepatitis C viral (HCV) infections prevents sequelae and onward transmission. In Germany, HCV drug prescriptions have declined since 2015. During the COVID-19 pandemic, lockdowns impacted the access to HCV care services and HCV treatment. We assessed if the COVID-19 pandemic further decreased treatment prescriptions in Germany. We built log-linear models with monthly HCV drug prescription data from pharmacies from January 201…

  • Recommandations pour la prise en charge de l’infection par le virus de l’hépatite C chez les usagers de drogues par injection

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2023

  • Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2023

  • Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2023

Hepatitis B Virus Studies (7 obras) · Hepatitis C virus research (7 obras) · Medicine (7 obras) · Liver Disease Diagnosis and Treatment (4 obras) · Virus (4 obras) · Hepatitis C virus (3 obras) · Internal Medicine (3 obras) · Disease (2 obras) · Family medicine (2 obras) · Gynecology (2 obras)

Ethnos_APP • Projeto Open Source • Licença MIT • Frontend v2.0.0 • Privacidade e Cookies • Documentação da API: api.ethnos.app/docs • Código da API: GitHub • DOI: 10.5281/zenodo.17049435 • Código do Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae